[October 26, 2004] FDA, Janssen Pharmaceutica Products, and Johnson & Johnson Pharmaceutical Research & Development notified healthcare professionals of reports of medication errors involving confusion between Reminyl, a drug approved for the treatment of mild to moderate dementia of the Alzheimer’s type, and Amaryl (glimepiride), a product of Aventis Pharmaceuticals, indicated for the treatment of non-insulin dependent (Type 2) diabetes mellitus. These reports include instances in which Reminyl was prescribed but Amaryl was incorrectly dispensed and administered instead, leading to various adverse events including severe hypoglycemia and one death.
Most important information about Amaryl
More information about AMARYL (Glimepiride):
Amaryl-Metformin Combination Therapy
Amaryl-Insulin Combination Therapy
To buy Amaryl click HERE: My Family Drugstore
Tags: Amaryl (Glimepiride), Conditions & Treatments, Medications, Type 2 Diabetes